Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono files Pergonal suit against FDA to reverse approval of Ferring generic menotropins.

Executive Summary

SERONO MENOTROPINS SUIT DEMANDS REVERSAL OF FERRING ANDA APPROVAL for a generic version of Pergonal. Serono v. Shalala and Friedman was filed by Serono attorneys Fox Bennett & Turner in Washington, D.C. District Court on May 30. The suit alleges that "FDA relied on Serono's injectable menotropins product for infertility -- Pergonal -- in approving the Ferring ANDA, even though the active and inactive ingredients in Pergonal are different from the ingredients in the Ferring generic product." FDA approved the Ferring NDA on Jan. 30.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel